Skip to content

Advertisement

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Low-dose aspirin and survival from lung cancer: a population-based cohort study

  • Úna C. Mc Menamin1Email author,
  • Chris R. Cardwell1,
  • Carmel M. Hughes2 and
  • Liam M. Murray1, 3
BMC Cancer201515:911

https://doi.org/10.1186/s12885-015-1910-9

Received: 25 February 2015

Accepted: 5 November 2015

Published: 17 November 2015

Abstract

Background

Preclinical evidence suggests that aspirin may inhibit lung cancer progression. In a large cohort of lung cancer patients, we investigated whether low-dose aspirin use was associated with a reduction in the risk of lung cancer-specific mortality.

Methods

We identified lung cancer patients from English cancer registries diagnosed between 1998 to 2009 from the National Cancer Data Repository. Medication usage was obtained from linkages to the UK Clinical Practice Research Datalink and lung cancer-specific deaths were identified from Office of National Statistics mortality data. Hazard ratios (HR) and 95 % confidence intervals (CI) for the association between low-dose aspirin use (before and after diagnosis) and risk of lung cancer-specific mortality were calculated using Cox regression models.

Results

A total of 14,735 lung cancer patients were identified during the study period. In analysis of 3,635 lung cancer patients, there was no suggestion of an association between low-dose aspirin use after diagnosis and cancer-specific mortality (adjusted HR = 0.96, 95 % CI: 0.85, 1.09). Similarly, no association was evident for low-dose aspirin use before diagnosis and cancer-specific mortality (adjusted HR = 1.00, 95 % CI: 0.95, 1.05). Associations were comparable by duration of use and for all-cause mortality.

Conclusion

Overall, we found little evidence of a protective association between low-dose aspirin use and cancer-specific mortality in a large population-based lung cancer cohort.

Keywords

CPRDLow-dose aspirinLung cancer survivalPharmacoepidemiology

Background

It is increasingly recognised that platelets play a critical role in the progression of cancer [13]. The use of aspirin, a commonly prescribed anti-platelet agent, after cancer diagnosis has been associated with a reduction in the risk of recurrence or cancer-specific mortality in colorectal [4, 5], breast [6, 7] and prostate [8] cancer cohorts. Partly motivated by these studies, a large phase 3 randomised trial of aspirin as adjunct treatment is soon to commence including patients at these sites [9]. A similar trial in lung cancer patients was planned but not conducted [10]. Accruing preclinical data suggest that aspirin may have anti-cancer properties [11, 12] by suppressing cellular proliferation [13], reducing neo-vascularisation [14] and inhibiting cell migration and the formation of metastases [15, 16]. Few epidemiological studies have examined the impact of aspirin on the progression of lung cancer, despite promising in vivo preclinical evidence of relevance to lung cancer [17, 18] and evidence that lung cancer patients previously exposed to low-dose aspirin present with more favourable tumour characteristics [19]. Only one epidemiological study has investigated cancer-specific outcomes in users of aspirin after lung cancer diagnosis, a time period when clinical intervention is possible. In a small cohort of 643 patients diagnosed with stage III non-small cell lung cancer, Wang et al. [20] reported a substantial, albeit non-significant reduction in the risk of distant cancer metastasis in users of aspirin (but not specifically low-dose) during definitive radiotherapy. Other studies have investigated aspirin use and overall survival but these results could reflect mortality from non-cancer causes. A cohort study of 1,765 non-small cell lung cancer patients reported a significant improvement in overall survival among those using aspirin (but not specifically low-dose) pre-operatively [21]. No difference in the rate of overall survival was observed in patients assigned to an anti-inflammatory daily dose of 1000 mg aspirin compared to non-treatment in a small randomised trial of 303 small cell lung cancer patients [22]. These 3 studies provide limited information as they were not population-based [20, 21], did not investigate low-dose aspirin solely and used limited time-points to ascertain drug exposure. Further epidemiological studies of the impact of low-dose aspirin use on lung cancer progression are therefore warranted to inform the conduct of randomised trials of low dose aspirin as adjunct treatment in lung cancer patients.

In a large population-based cohort of cancer-registry confirmed lung cancer patients utilising detailed prescribing records, we aimed to investigate whether low-dose aspirin use, either before and after diagnosis, was associated with a reduced cancer-specific mortality.

Methods

Data sources

This study utilised record linkages between the National Cancer Data Repository (NCDR), the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) and the Office of National Statistics (ONS) death registration data. The NCDR contains data on cancer patients diagnosed in England including the date and site of primary cancer diagnoses, as well as information on cancer treatments received. The CPRD is the world’s largest computerised dataset of anonymised longitudinal primary care records covering approximately 7 % of the United Kingdom population. It comprises general practice records of documented high quality [23, 24] containing demographics, clinical diagnoses and prescriptions issued. Date and cause of death was provided by ONS death registrations. The CPRD group obtained ethical approval from a Multicentre Research Ethics Committee (MREC) for purely observational research using data from the database, such as ours. This study obtained approval from the Independent Scientific Advisory Committee (ISAC) of the CPRD, which is responsible for reviewing protocols for scientific quality.

Study design

Between 1998 and 2009, all patients newly diagnosed with primary lung cancer (International Classification of disease, ICD code C34) were identified from the NCDR. Patients with a previous NCDR cancer diagnosis were excluded, with the exception of in situ neoplasms and non-melanoma skin cancers. Using ONS death registration data, deaths were obtained up until January 2012 and lung cancer specific deaths were identified using an underlying cause of death ICD code C34.

Exposure data

General practitioner (GP)-recorded aspirin prescriptions, according to the British National Formulary [25], were classified as low if ≤75 mg (0.1 % of prescriptions after diagnosis 25 mg, 92.7 % were 75 mg and 7.3 % were >75 mg). The average quantity of 28 was assumed for approximately 2 % of prescriptions were quantity was missing or incorrect.

Covariates

Clinical data on tumour histology, and receipt of cancer treatments including surgery, chemotherapy and radiotherapy within 6 months after diagnosis was obtained from the NCDR. Tumour histology was based on cancer registry recorded International Classification of Diseases for Oncology codes (3rd Edition). Data on lifestyle factors including smoking, alcohol and BMI was derived from the closest GP records within 10 years prior to diagnosis. Clinical GP-recorded diagnoses were used to determine comorbidities prior to diagnosis, and comprised those which were included in a recent adaptation of the Charlson Comorbidity index [26]. A measure of deprivation was available from CPRD records based on the 2004 Index of Multiple Deprivation for England which comprises super output area (SOA) level measures of multiple deprivation (based on UK residential postcodes) and is made up of seven SOA level domain indices [27]. Patients were categorised into one of 5 quintiles of deprivation with the first quintile representing the least deprived and the fifth quintile representing the most deprived. Other medications including statins and beta-blockers, were determined from GP-prescription records and included in adjusted analyses due to potential associations with cancer-specific mortality.

Statistical analysis

Statistical analysis for low-dose aspirin use after diagnosis

In the analysis of low-dose aspirin use after diagnosis (regardless of pre-diagnostic low-dose aspirin use), lung cancer patients who died in the first year after diagnosis were excluded (sensitivity analysis was conducted varying this interval) as it is likely that these patients had stage IV disease and it seemed unlikely that short term post-diagnostic drug use would influence such deaths. Patients were therefore followed up from one year after diagnosis until death, end of registration with the general practice, last date of data collection from general practice or end of ONS follow-up. Time dependent Cox regression models were used to produce unadjusted and adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) for the association between low-dose aspirin use and lung cancer-specific mortality. Low-dose aspirin use was treated as time-varying, with users not considered to be exposed until after a lag of six months following their initial prescription. Other medications including statins and beta-blockers were treated in a similar manner. The use of a lag is recommended [28] and was used to exclude prescriptions in the six months prior to death as these may reflect changes due to end of life care. Medications may be withdrawn from cancer patients in whom death is suspected to be imminent and unlagged time-varying covariate analysis can bias results due to reverse causality [29]. Dose–response relationships were investigated by cumulative number of prescriptions and increasing number of tablets during the exposure period, and analyses were repeated for all-cause mortality. Sub-group analyses were carried out by sex, pre-diagnostic low-dose aspirin use, histology and surgery within 6 months after diagnosis. Tests for interactions were performed for each sub-group analysis. Separate sensitivity analyses were conducted by: increasing the lag from 6 months to 1 year (thereby excluding prescriptions in the year prior to death); only excluding those who died within the first six months after diagnosis (thereby including more of the cohort); and additionally adjusting for smoking, BMI and histological sub-type. A simplified analysis was conducted assessing the influence of low-dose aspirin use versus non-use in the first year after lung cancer diagnosis among patients who survived at least one year after diagnosis. In order to verify the robustness of results (i.e. if the findings are similar to the main analysis it would suggest that our results are robust), the entire cohort was converted to case–control data to carry out a nested case–control analysis using conditional logistic regression. Cases were patients that died due to lung cancer and were matched on sex, age (in 5 year bands) and year of diagnosis (in 2 year bands) to five risk-set controls that lived at least as long after their lung cancer diagnosis, thereby eliminating immortal time bias [30]. Odds ratios (ORs) and 95 % confidence intervals (CIs) were produced using conditional logistic regression to examine the association between low-dose aspirin use and lung cancer-specific mortality.

Statistical analysis for low-dose aspirin use before diagnosis

In the analyses of low-dose aspirin use before lung cancer diagnosis, follow-up began from diagnosis until death or censoring (as described earlier). Patients who died in the first year after diagnosis were not excluded. Cox regression models were used to calculate unadjusted and adjusted HRs and 95 % CIs based upon prescriptions in the year prior to diagnosis, among patients with at least 1 year of CPRD records prior to diagnosis. To prevent over-adjustment in the analysis of pre-diagnosis low-dose aspirin use, adjustments were only made for potential confounders recorded prior to cancer diagnosis [31, 32] (statin and beta-blocker use were also based upon prescriptions in the year prior to diagnosis). Analyses were conducted by cumulative number of low-dose aspirin prescriptions and increasing number of tablets within the exposure period, and repeated for all-cause mortality. Sub-group analyses were carried out by sex and sensitivity analyses included additional adjustment for smoking and BMI prior to diagnosis and extending the pre-diagnostic exposure period from 2 years to 6 months prior to diagnosis (among patients with at least 2 years of records prior to diagnosis).

Results

Patient cohort

A total of 14,735 lung cancer patients with linked CPRD data were identified from the NCDR. The analysis of aspirin use after diagnosis included 3,635 patients after excluding 11,100 patients with less than 1 year of follow-up (10,295 of whom had died). The analysis of aspirin use before diagnosis included 13,433 patients, after excluding 1,302 patients with less than 1 year of CPRD records prior to diagnosis. In the analysis of aspirin use after diagnosis average follow-up was 3 years (maximum 14 years) and in the analysis of aspirin use before diagnosis, average follow-up was 1 year (maximum 14 years).

Patient characteristics

Table 1 lists patient characteristics by low-dose aspirin use. Users of low-dose aspirin either before or after diagnosis were more likely to be diagnosed more recently, be older, be male and be overweight or obese prior to cancer diagnosis. The majority of comorbidities were also more common in users of aspirin (particularly cerebrovascular disease, diabetes and myocardial infarction), in addition to the use of statins and beta-blockers. Low-dose aspirin users after diagnosis were less likely to undergo chemotherapy. Other patient characteristics were not as strongly associated with the use of low-dose aspirin.
Table 1

Characteristics of lung cancer patients by low-dose aspirin use

Characteristics

Total study population

Low-dose aspirin use in year prior to diagnosisa

Low-dose aspirin use after diagnosisb

  

User n (%)

Non-user (%)

Ever n (%)

Never (%)

 

(n = 14,735)

(n = 13,433)

(n = 3,635)

Year of diagnosis: 1998–2000

2,797 (19)

459 (12)

1,850 (19)

175 (15)

463 (19)

 2001–2003

3,708 (25)

831 (22)

2,524 (26)

280 (24)

603 (24)

 2004–2006

4,025 (27)

1,175 (30)

2,603 (27)

322 (28)

647 (26)

 2007–2009

4,205 (29)

1,404 (36)

2,587 (27)

384 (33)

761 (31)

Age at diagnosis: < 50

492 (3)

11 (0)

410 (4)

10 (1)

163 (7)

 50–59

1,780 (12)

171 (4)

1,425 (15)

97 (8)

475 (19)

 60–69

3,912 (27)

916 (24)

2,660 (28)

362 (31)

804 (33)

 70–79

5,347 (36)

1,681 (44)

3,231 (34)

478 (31)

775 (31)

 80–89

2,898 (20)

974 (25)

1,677 (18)

199 (17)

242 (10)

 ≥90

306 (2)

116 (3)

161 (2)

15 (1)

15 (1)

Gender: Males

8,701 (59)

1,581 (63)

6,360 (58)

748 (64)

1,357 (55)

Treatment within 6 months of cancer diagnosis

 Surgeryc

1,324 (12)

329 (11)

895 (12)

305 (34)

567 (30)

 Chemotherapy

3,287 (22)

709 (18)

2,324 (24)

309 (27)

950 (38)

 Radiotherapy

4,668 (32)

1,129 (29)

3,100 (32)

389 (34)

989 (40)

Histology: Non-small cell

8,224 (56)

2,066 (53)

5,478 (57)

822 (71)

1,793 (73)

 Small cell

1,828 (12)

458 (12)

1,218 (13)

121 (10)

303 (12)

 Missing

4,683 (32)

1,345 (35)

2,868 (30)

218 (19)

378 (15)

Smoking status prior to cancer diagnosis

 Non-smoker

1,907 (13)

543 (14)

1,188 (12)

148 (13)

339 (14)

 Ex-smoker

5,214 (35)

1,754 (45)

3,111 (33)

541 (47)

852 (34)

 Current smoker

5,961 (41)

1,329 (34)

4,138 (43)

393 (34)

1,042 (42)

 Missing

1,653 (11)

243 (6)

1,127 (12)

79 (7)

241 (10)

Alcohol consumption prior to diagnosis

 Never

2,311 (16)

727 (19)

1,385 (15)

190 (16)

342 (14)

 Ever

9,707 (66)

2,678 (69)

6,337 (66)

841 (72)

1,712 (69)

 Missing

2,717 (18)

464 (12)

1,842 (19)

130 (11)

420 (17)

BMI (kg/m2) prior to diagnosis: mean (sd)

 Underweight (<18.5)

735 (5)

175 (5)

487 (5)

38 (3)

100 (4)

 Normal (18.5 to 25)

5,325 (36)

1,379 (36)

3,543 (37)

401 (35)

943 (38)

 Overweight (25–30)

3,916 (27)

1,199 (31)

2,444 (26)

388 (33)

695 (28)

 Obese (>30)

1,702 (12)

602 (16)

1,002 (11)

196 (17)

287 (12)

 Missing

3,057 (21)

514 (13)

2,088 (22)

138 (12)

449 (18)

Deprivation fifth: 1st (least deprived)

2,583 (18)

650 (17)

1,696 (18)

206 (18)

481 (19)

 2nd

2,822 (19)

754 (20)

1,833 (19)

236 (20)

451 (18)

 3rd

2,975 (20)

778 (20)

1,954 (20)

232 (20)

492 (20)

 4th

3,235 (22)

815 (21)

2,102 (22)

250 (22)

556 (23)

 5th (most deprived)

3,062 (21)

859 (22)

1,947 (20)

233 (20)

489 (20)

 Missing

58 (0)

13 (0)

32 (0)

4 (0)

5 (0)

Comorbidity prior to cancer diagnosis

 Cerebrovascular disease

1,.325 (9)

746 (19)

498 (5)

147 (13)

95 (4)

 Chronic pulmonary disease

3,619 (25)

1,054 (27)

2,341 (25)

307 (26)

621 (25)

 Congestive heart disease

954 (7)

413 (11)

483 (5)

83 (7)

76 (3)

 Diabetes

1,552 (11)

758 (20)

698 (7)

194 (17)

141 (6)

 Myocardial infarction

1,262 (9)

866 (22)

316 (3)

223 (19)

67 (3)

 Peptic ulcer disease

1,087 (7)

264 (7)

745 (8)

65 (6)

182 (7)

 Peripheral vascular disease

1,422 (10)

780 (20)

576 (6)

200 (17)

127 (5)

 Renal disease

864 (6)

441 (11)

397 (4)

97 (8)

99 (4)

Other medication use after diagnosis

 Statin used

4,801 (33)

2,103 (54)

1,193 (13)

705 (61)

410 (17)

 Beta-blocker used

3,823 (26)

1,143 (30)

1,005 (11)

416 (36)

272 (11)

aAnalysis includes lung cancer patients who have more than 1 year of records prior to diagnosis

bPost-diagnostic aspirin use (regardless of pre-diagnostic aspirin use), among lung cancer patients who lived more than 1 year after diagnosis

cExcluding cancer patients from Thames Registry as surgery information not available

dStatin and beta-blocker use ever after diagnosis for low-dose aspirin use after diagnosis columns, statins and beta-blocker use in year prior to diagnosis for low-dose aspirin use in year prior to diagnosis columns, statins and beta-blocker use either before or after diagnosis in total study population column

Association between low-dose aspirin use after diagnosis and survival

There was no evidence of an association between low-dose aspirin use after diagnosis and lung cancer-specific mortality (HR = 0.96, 95 % CI: 0.87, 1.05), as shown in Table 2. No dose–response relationship was evident by increasing prescriptions of low-dose aspirin, or by tablets. Similarly, no difference in the rate of all-cause mortality was observed between users of low-dose aspirin and non-users, Table 2. Adjustment for potential confounders including cancer treatments and comorbidities did not materially alter risk estimates. In sub-group analyses, associations between low-dose aspirin use and cancer-specific mortality did not differ by sex, pre-diagnostic low-dose aspirin use or surgical treatment, see Table 3. There was a suggestion of a small, although not statistically significant, reduction in the risk of cancer-specific mortality in patients diagnosed with small cell lung cancer using low-dose aspirin after diagnosis (adjusted HR = 0.72, 95 % CI: 0.52, 1.01; P for interaction = 0.034). Results from sensitivity analyses were comparable to that of the main analysis, Table 3.
Table 2

Association between low-dose aspirin usage after cancer diagnosis and cancer-specific and all-cause mortality in lung cancer patients

Medication usage after diagnosis

Cancer-specific deaths

All-cause mortality

All patients

Person years

Cancer-specific mortality

All-cause mortality

Unadjusted

P

Adjusteda

P

Unadjusted

P

Adjusteda

P

     

HR

95 % CI

 

HR

95 % CI

 

HR

95 % CI

 

HR

95 % CI

 

Number of patients

    

[n = 3,635]

 

[n = 2,791]

 

[n = 3,635]

 

[n = 2,791]

 

Aspirin non-user

1,609

1,855

2,474

4,481

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

Aspirin userb

638

795

1,161

2,264

0.96

0.87, 1.05

0.36

0.96

0.85, 1.09

0.55

1.00

0.92, 1.09

0.92

0.94

0.84, 1.05

0.28

Aspirin non-user

1,609

1,855

2,474

4,481

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

Aspirin user 1 to 11 prescriptionsc

440

521

670

1,189

0.94

0.85, 1.04

0.25

0.95

0.83, 1.08

0.42

0.97

0.88, 1.07

0.60

0.93

0.83, 1.05

0.24

Aspirin user ≥ 12 prescriptionsc

198

274

491

1,075

1.00

0.86, 1.17

0.96

1.01

0.84, 1.23

0.89

1.07

0.94, 1.23

0.29

0.97

0.82, 1.14

0.69

Aspirin non-user

1,609

1,855

2,474

4,481

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

Aspirin user 1–365 tabletsc

353

422

541

926

0.91

0.81, 1.02

0.12

0.92

0.80, 1.06

0.27

0.96

0.86, 1.07

0.44

0.92

0.81, 1.05

0.21

Aspirin user ≥366 tabletsc

285

373

620

1,338

1.03

0.90, 1.17

0.69

1.04

0.88, 1.23

0.67

1.07

0.95, 1.20

0.28

0.97

0.84, 1.13

0.72

aAdjusted for year of diagnosis, age at diagnosis, gender, radiotherapy within 6 months, chemotherapy within 6 months, surgery within 6 months, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (after diagnosis, as time varying covariates, specifically statins and beta-blockers) and deprivation (in fifths)

bMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage and a user after this time, excludes deaths in the year after cancer diagnosis

cMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage, a user of 0 to 12 prescriptions from 6 months after first prescription to 6 months after 12th prescription (or 365 tablets) and a greater user after this time, excludes deaths in the year after cancer diagnosis

Table 3

Sensitivity analyses for association between low-dose aspirin use and cancer-specific mortality in lung cancer patients

 

Cancer-specific deaths

All patients

Person years

User versus non-user

User versus non-user

 

Unadjusted

P

Adjusted HRa

P

P for interaction

    

HRa

95 % CI

 

HRa

95 % CI

  

Main analysis: Aspirin user versus non-user after diagnosis

2,247

3,635

6,745

0.96

0.87, 1.05

0.36

0.96

0.85, 1.09

0.55

 

Sub group analyses: Aspirin user versus non-user after diagnosis, restricted to:

        

 Males

1,312

2,105

3,750

1.00

0.89, 1.12

0.97

1.05

0.90, 1.22

0.54

0.12

 Females

935

1,530

2,995

0.87

0.75, 1.02

0.08

0.81

0.66, 0.99

0.05

 Pre-diagnosis aspirin non-usersb

1,515

2,446

4,578

0.89

0.74, 1.07

0.21

0.91

0.73, 1.14

0.42

0.48

 Pre-diagnosis aspirin usersb

554

908

1,601

0.92

0.72, 1.16

0.47

1.02

0.77, 1.35

0.90

 Small cell lung cancer

328

424

592

0.84

0.66, 1.09

0.19

0.72

0.52, 1.01

0.05

0.03

 Non-small cell lung cancer

1,523

2,615

5,355

0.95

0.85, 1.06

0.35

1.00

0.86, 1.16

0.99

 Surgically treated

305

872

2,714

0.99

0.78, 1.27

0.96

0.95

0.71,1.28

0.74

0.39

 Non-surgically treated

820

1,708

4,216

0.94

0.80, 1.10

0.42

0.89

0.74, 1.07

0.22

Sensitivity analyses: Aspirin user versus non-user after diagnosis

        

 Increasing lag to 1 year

2,247

3,635

6,745

0.97

0.88, 1.07

0.56

0.97

0.85, 1.10

0.60

 

 Excluding patients who died within the first 6 months after diagnosis

4,440

6,158

9,101

0.96

0.90, 1.03

0.28

0.95

0.87–1.04

0.30

 

 Additionally adjusting for smoking prior to diagnosis

2037

3,315

6,074

0.95

0.86, 1.04

0.28

0.95

0.84, 1.08

0.41

 

 Additionally adjusting for BMI prior to diagnosis

1,849

3,048

5,640

0.93

0.84, 1.03

0.15

0.95

0.84, 1.09

0.47

 

 Additionally adjusting for small cell/non-small cell

1,851

3,039

5,947

0.92

0.83, 1.03

0.14

0.92

0.80, 1.05

0.23

 

 Based upon first year after diagnosisc

1,728

2,791

5,223

0.93

0.87, 1.05

0.33

0.99

0.88, 1.13

0.91

 

 Nested case–control analysisd,e

2,247

  

0.93

0.85, 1.03

0.19

1.00

0.86, 1.16

0.97

 

aExcept where otherwise stated, all analyses of post-diagnostic aspirin use adjusted for year of diagnosis, age at diagnosis, gender, surgery within 6 months of diagnosis, radiotherapy within 6 months, chemotherapy within 6 months, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (after diagnosis, as time varying covariates, specifically statins and beta-blockers) and deprivation (in fifths)

bBased upon aspirin use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis

cSimplified analysis, not requiring time varying covariate use, comparing aspirin users to aspirin non-users in the first year after diagnosis in individuals living more than 1 year after cancer diagnosis, adjusted for all confounders ina but other medication use also restricted to first year after diagnosis

dUnadjusted OR estimate and 95 % CIs based on 28 % (623/2,247) of cancer-specific deaths using aspirin compared with 31 % (3,254/10,603) of risk-set controls (not dying from cancer)

eAdjusted OR estimate and 95%CIs, matched on age at diagnosis, year of diagnosis, gender and adjusted for all other confounders ina

Association between low-dose aspirin use before diagnosis and survival

Overall, no association between aspirin use prior to diagnosis and lung cancer-specific mortality was observed (adjusted HR = 1.00, 95 % CI: 0.95, 1.05) and no dose–response relationship was apparent in analyses by increasing prescriptions or tablets, Table 4. Similar associations were observed across sub-group and sensitivity analyses; for example, after additional adjustment for smoking and BMI (Table 5).
Table 4

Association between low-dose aspirin usage in the year prior to diagnosis and cancer-specific and all-cause mortality in lung cancer patients

Medication usage after diagnosis

Cancer-specific deaths

All-cause mortality

All patients

Person years

Cancer-specific mortality

All-cause mortality

Unadjusted

P

Adjusteda

P

Unadjusted

P

Adjusteda

P

     

HR

95 % CI

 

HR

95 % CI

 

HR

95 % CI

 

HR

95 % CI

 

Number of patients

    

[n = 13,433]

 

[n = 13,388]

 

[n = 13,433]

 

[n = 13,388]

 

Aspirin non-user

7,577

8,369

9,564

9,154

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

1.00

Referent

 

Aspirin user

3,055

3,468

3,869

3,331

1.07

1.02, 1.11

<0.01

1.00

0.95, 1.05

0.91

1.10

1.05, 1.14

<0.001

1.01

0.96, 1.06

0.77

Aspirin non-user

7,577

8,369

9,564

9,154

1.00

Referent

 

1.00

Referent

 

1.00

1.00

 

1.00

Referent

 

Aspirin user 1 to 11 prescriptions

2,367

2,690

2,998

2,608

1.06

1.01, 1.11

0.02

0.99

0.94, 1.04

0.75

1.09

1.04, 1.14

<0.001

1.00

0.95, 1.05

0.90

Aspirin user ≥ 12 prescriptions

688

778

871

723

1.09

1.01, 1.18

0.03

1.02

0.94, 1.11

0.64

1.11

1.04, 1.20

<0.01

1.02

0.95, 1.11

0.57

Aspirin non-user

7,577

8,369

9,564

9,154

1.00

Referent

 

1.00

Referent

 

1.00

1.00

 

1.00

Referent

 

Aspirin user 1–365 tablets

2,214

2,508

2,804

2,436

1.06

1.01, 1.12

0.01

1.00

0.95, 1.06

0.97

1.09

1.04, 1.14

<0.001

1.01

0.96, 1.06

0.70

Aspirin user ≥366 tablets

841

960

1,065

895

1.07

1.00, 1.15

0.06

0.98

0.91, 1.06

0.70

1.11

1.04, 1.18

<0.01

1.00

0.93, 1.07

0.97

aAdjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically statins and beta-blockers) and deprivation (in fifths)

Table 5

Sensitivity analyses for association between low-dose aspirin use and cancer-specific mortality in lung cancer patients

 

Cancer-specific deaths

All patients

Person years

Unadjusted

P

Adjusteda

P

    

HR

95 % CI

 

HR

95 % CI

 

Main analysis: Pre-diagnostic aspirin useb

10,632

13,433

12,485

1.07

1.02, 1.11

<0.01

1.00

0.95, 1.05

0.91

Subgroup analyses

         

 Male

6,298

7,941

7,103

1.02

0.97, 1.08

0.44

0.98

0.91–1.04

0.46

 Female

4,334

5,492

5,381

1.13

1.06–1.21

<0.001

1.03

0.95–1.11

0.53

Sensitivity analyses

         

 Smoking prior to diagnosis available (and adjusted for)

9,560

12,063

11,336

1.07

1.03–1.12

<0.01

1.00

0.95–1.05

0.93

 BMI prior to diagnosis available (and adjusted for)

8,562

10,831

10,448

1.07

1.02–1.12

<0.01

0.99

0.94–1.05

0.73

 Aspirin use between 2 years and 6 months prior to diagnosisc

9,746

12,295

11,418

1.06

1.01–1.11

0.01

0.99

0.94–1.05

0.76

aExcept where otherwise stated, adjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically statins and beta-blockers) and deprivation (in fifths)

bBased upon use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis

cRestricted to individuals with 2 years of records prior to diagnosis, removing prescriptions in the 6 months prior to lung cancer diagnosis as these could reflect increased medical care due to early symptoms

Discussion

In this population-based study, we did not find evidence of a protective association between low-dose aspirin use and cancer-specific or all-cause mortality in a large cohort of lung cancer patients. Only one previous study has assessed the impact of aspirin on lung cancer-specific outcomes. An American study of 643 non-small cell lung cancer patients conducted by Wang et al. [20] observed a substantial non-significant decrease in the risk of distant metastasis in users of aspirin (but not specifically low-dose) after diagnosis (HR = 0.75, 95 % CI: 0.55–1.03). Inconsistencies between the findings of this study and ours could reflect differences in the methodologies employed. Their study was hospital-based, used a different outcome (distant metastasis), as well as a different method to ascertain aspirin exposure (based upon patient recall during the receipt of definitive radiotherapy). A further study by Fontaine et al. [21], based in the UK, observed a significant reduction in all-cause mortality among pre-operative users of aspirin (HR = 0.84, P = 0.05). The authors hypothesised that the observed benefit in all-cause mortality may be due to an improvement in cardiovascular-related mortality, as the reduction in risk was most evident after 3 years [21]. In contrast, we found no evidence of a protective association between low-dose aspirin use and all-cause mortality. A meta-analysis of randomised controlled trials of low-dose aspirin (in patients with increased cardiovascular risk) observed reduced mortality due to lung cancer but this largely reflected lung cancer incidence as patients were cancer-free at randomisation [33]. Our study only investigated low-dose aspirin, hence we cannot rule out a possible benefit of high-dose cycloxygenase (COX)-2 inhibitory aspirin. A previous study, although relatively small and based on patient report, did not observe an association between pre-diagnostic high- or low-dose aspirin and lung cancer survival [34]. Furthermore, our study contained relatively few very long term low-dose aspirin users (i.e. more than 5 years) and therefore it is difficult to comment on the effect of very long term aspirin use.

In sensitivity analyses, we observed a non-significant 28 % reduction in risk of lung cancer-specific mortality with post-diagnostic aspirin use in patients diagnosed with small cell lung cancer. Caution however is required in the interpretation of this finding as this was not an a priori defined subgroup analysis and was based on substantially smaller numbers compared to the main analysis (328 versus 2,247 deaths, respectively).

Our study had a number of strengths and limitations. This is the first study to evaluate the impact of low-dose aspirin use and lung cancer-specific mortality. The cohort was identified from the NCDR, a large population-based resource which allowed for robust verification of cancer diagnoses. Similarly, deaths could be confirmed using ONS. Some misclassification of deaths could have occurred but evidence from methodological comparative studies suggest that risk estimates are unlikely to be greatly affected [35]. The use of high-quality [22] GP-recorded prescriptions allowed for detailed investigation of temporal associations and eliminates potential for recall bias. Over-the-counter usage of low-dose aspirin is possible but previous investigation within the General Practice Research Database found that the majority of chronic aspirin use was captured by prescription records [36]. Furthermore, valid treatment risk estimates have been previously demonstrated when there is potential for over-the-counter medication usage [37]. Drug compliance was unknown in this study but similar results were produced in analysis of multiple prescriptions, in which drug adherence may be more likely. Although we adjusted for a range of potential confounding factors, residual confounding caused by unrecorded or incomplete data cannot be ruled out. More specifically, we were unable to adjust for cancer stage in our analyses; however, as stage may lie on the causal pathway, such adjustments may not be appropriate for the analysis of low-dose aspirin use before diagnosis. Finally, although follow-up time after diagnosis was up to 14 years in both analysis of post-diagnostic and pre-diagnostic low-dose aspirin use, the average follow-up time in each analysis was substantially shorter reflecting poor survival after lung cancer diagnosis (3 years and 1 year, respectively).

Conclusions

In this population-based study, low-dose aspirin use was not associated with an improvement in cancer survival in a large cohort of cancer-registry confirmed lung cancer patients.

Consent statement

Informed patient consent was not required for this study.

Abbreviations

BMI: 

body mass index

CIs: 

confidence intervals

CPRD: 

clinical practice research datalink

GP: 

general practitioner

HR: 

hazard ratio

ICD: 

International classification of diseases

NCDR: 

National cancer data repository

ONS: 

Office of national statistics

OR: 

Odds ratio

UK: 

United Kingdom

Declarations

Acknowledgments

CRC and UMM were supported by a Health and Social Care Research and Development, Public Health Agency, Northern Ireland, funded UK NIHR Career Development Fellowship, which also funded access to the CPRD dataset. This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. However, the interpretation and conclusions contained in this study are those of the authors alone.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Cancer Epidemiology and Health Services Research Group, Centre for Public Health, Queen’s University Belfast, Belfast, UK
(2)
School of Pharmacy, Queen’s University Belfast, Belfast, UK
(3)
Centre of Excellence for Public Health (NI), Centre for Public Health, Queen’s University Belfast, Belfast, UK

References

  1. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci. 1968;61(1):46–52.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–49.View ArticlePubMedGoogle Scholar
  3. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34.View ArticlePubMedGoogle Scholar
  4. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–606.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015;107(1):345.View ArticlePubMedGoogle Scholar
  6. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2012;46(13):2473–8.Google Scholar
  7. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467–72.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30(28):3540–4.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Langley RE, Wilson RH, Ring A, Kynaston HG, Murphy CM, Cameron DA, et al. Evidence for the use of aspirin as a treatment for cancer and the planned Add-Aspirin trial. Berlin, Germany: The First World Congress on Controversies in Gastroenterology; 2013. Available from: http://www.comtecmed.com/cigi/2013/Abstracts_Text.aspx. Accessed January 2015.Google Scholar
  10. United States National Institutes of Health: Study record detail: the effect of aspirin on survival in lung cancer: study record detail. Available from: https://clinicaltrials.gov/ct2/show/NCT01058902. Accessed January 2015.
  11. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009;373(9671):1301–9.View ArticlePubMedGoogle Scholar
  12. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MKB, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107–13.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Din FVN, Valanciute A, Houde VP, Zibrova D, Green K, Sakamoto K, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):1504–15.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J. 2006;20(12):2009–16.View ArticlePubMedGoogle Scholar
  15. Lloyd Jr FP, Slivova V, Valachovicova TSD. Aspirin inhibits highly invasive prostate cancer cells. Int J Oncol. 2003;23(5):1277–83.PubMedGoogle Scholar
  16. Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer. 2015;136(2):462–75.View ArticlePubMedGoogle Scholar
  17. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18(5):1001–6.View ArticlePubMedGoogle Scholar
  18. Ogawa F, Amano H, Ito Y, Matsui Y, Hosono K, Kitasato H, et al. Aspirin reduces lung cancer metastasis to regional lymph nodes. Biomed Pharmacother. 2014;68(1):79–86.View ArticlePubMedGoogle Scholar
  19. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y. Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer. 2013;109(7):1921–5.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Wang H, Liao Z, Zhuang Y, Liu Y, Levy LB, Xu T, et al. Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy. Clin Lung Cancer. 2014. doi:10.1016/j.cllc.2014.09.006.Google Scholar
  21. Fontaine E, McShane J, Page R, Shackcloth M, Mediratta N, Carr M, et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg. 2010;38(1):21–6.View ArticlePubMedGoogle Scholar
  22. Lebeau B, Chastang MDMJ. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVPI 6 chemotherapy. Cancer. 1992;71(5):1741–5.View ArticleGoogle Scholar
  23. Jick H, LE Jick SSD. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J. 1991;302:766–8.View ArticleGoogle Scholar
  24. Boggon R, Van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf. 2013;22:168–75.View ArticlePubMedGoogle Scholar
  25. British medical association and the royal pharmaceutical society of great Britain: British national formulary. Available from: http://www.bnf.org/products/bnf-online/. Accessed January 2015.
  26. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract. 2010;11:1.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Noble M, Wright G, Dibben C, Smith GAN, McLennan D, Anttila C, et al. Indices of deprivation 2004: Report to the office of the deputy prime minister. London, UK: Neighb Renew Unit; 2004.Google Scholar
  28. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013;105(19):1456–62.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Tamim H, Monfared AAT, Lelorier J. Application of lag time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf. 2007;16:250–8.View ArticlePubMedGoogle Scholar
  30. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16:241–9.View ArticlePubMedGoogle Scholar
  31. Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol. 1993;137(1):1–3.PubMedGoogle Scholar
  32. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–95.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.View ArticlePubMedGoogle Scholar
  34. Brasky TM, Baik CS, Slatore CG, Alvarado M, White E. Pre-diagnostic non-steroidal anti-inflammatory drug use and cancer survival in the VITAL study. J Thorac Oncol. 2012;7:1503–12.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol. 2010;39(2):598–610.View ArticlePubMedGoogle Scholar
  36. Yang Y, Pharmd SH, Propert K, Hwang W, Sarkar M, Lewis JD. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf. 2008;17:869–76.Google Scholar
  37. Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf. 2007;16(9):961–8.View ArticlePubMedGoogle Scholar

Copyright

© Mc Menamin et al. 2015

Advertisement